Selexys' sickle cell disease drug is entering Phase II trial

08/20/2013 | Oklahoman (Oklahoma City), The

Selexys Pharmaceuticals has started patient enrollment for a midstage study of the experimental sickle cell disease drug SelG1. The trial, which will involve about 175 patients, will evaluate the drug's safety and efficacy with the goal of decreasing the frequency of sickle cell-related pain crises.

View Full Article in:

Oklahoman (Oklahoma City), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Vice President, Idaho Regional Director
PacificSource
Boise, ID
Counsel II, Legal (Anti-corruption)
Gilead Sciences
Foster City, CA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA